Smart trial two-year data continues to demonstrate superior valve performance for evolut tavr™ system in small annulus patients

Crt 2025 late breaking science features largest head-to-head randomized control tavr trial to primarily enroll women using the two most widely used global tavr devices galway, ireland and washington , march 9, 2025 /prnewswire/ -- medtronic plc (nyse: mdt), a global leader in healthcare technology, today released the two-year results of the small a nnuli r andomized t o evolut or sapien (smart) trial, the largest international head-to-head comparative trial of transfemoral transcatheter aortic valve replacement (tavr). in patients with aortic stenosis and a small aortic annulus, results showed comparable composite outcome of mortality, disabling stroke, and heart failure hospitalization, and continued superior valve performance as measured by bioprosthetic valve dysfunction (bvd) at two years for evolut™ tavr compared to sapien™.
MDT Ratings Summary
MDT Quant Ranking